Modeling and Simulation - PK/PD Archives | Page 21 of 44

Brochure

Phoenix NLME, The Modern PK/PD Modeling Software for Today’s Scientists

Phoenix NLME is the PK/PD modeling software that is user-friendly and easy-to-learn. Built from the…

CertaraSeptember 12, 2016

Brochure

Rare Disease and Orphan Drug Development

There are 7,000 rare diseases impacting 350 million patients worldwide, yet only 300 of these…

CertaraAugust 3, 2016

Publication

Population Pharmacokinetics of Bevacizumab in Cancer Patients with External Validation

CertaraAugust 1, 2016

Publication

Prediction of Altered Bile Acid Disposition Due to Inhibition of Multiple Transporters: An Integrated Approach Using Sandwich-cultured Hepatocytes, Mechanistic Modeling, and Simulation

CertaraAugust 1, 2016

White Paper

Model-based Meta-analysis: An Innovative Methodology Comes of Age

MBMA integrates internal and external drug development data to inform proprietary commercial and R&D decisions.…

CertaraJuly 14, 2016

Publication

Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients with Renal Impairment

Avibactam is a non-β-lactam β-lactamase inhibitor intended for use as a fixed-dose combination with ceftazidime…

CertaraJuly 12, 2016

Publication

More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-mediated Clearances

Rosuvastatin is a substrate of choice in clinical studies of organic anion-transporting polypeptide (OATP)1B1- and…

CertaraJuly 1, 2016

Publication

Pharmacokinetic Profile of Defibrotide in Patients with Renal Impairment

Hepatic veno-occlusive disease, also called sinusoidal obstruction syndrome (VOD/SOS), is an unpredictable, potentially life-threatening complication…

CertaraJune 11, 2016

Blog

Diving into Best Practices for Pooling Clinical Trial Data

Learn the best practices for pooling clinical trial data. Discover how effective data integration enhances…

CertaraJune 3, 2016

Publication

Lessons Learned: Dose Selection of Small Molecule-targeted Oncology Drugs

CertaraJune 1, 2016

Modeling and Simulation – PK/PD

Phoenix NLME, The Modern PK/PD Modeling Software for Today’s Scientists

Rare Disease and Orphan Drug Development

Population Pharmacokinetics of Bevacizumab in Cancer Patients with External Validation

Prediction of Altered Bile Acid Disposition Due to Inhibition of Multiple Transporters: An Integrated Approach Using Sandwich-cultured Hepatocytes, Mechanistic Modeling, and Simulation

Model-based Meta-analysis: An Innovative Methodology Comes of Age

Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients with Renal Impairment

More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-mediated Clearances

Pharmacokinetic Profile of Defibrotide in Patients with Renal Impairment

Diving into Best Practices for Pooling Clinical Trial Data

Lessons Learned: Dose Selection of Small Molecule-targeted Oncology Drugs

Newsletter sign up

Quick links

Solutions

Contact